The study, performed by researchers at the Vanderbilt Heart and Vascular Institute, compared a cohort of patients with risk factors for CIED infection who received CIED implantations with TYRX’s AIGISRx Antibacterial Envelope to those with risk factors who received implantations without the envelope. The antibacterial envelope releases the antibiotics Minocycline and rifampin in order to reduce SSIs.
After 90 days, the rate of CIED infection was significantly lower (0.04 percent) for patients who received implantations with the antibacterial envelope than for those who did not (3.0 percent).
More Articles on SSIs:
New York Hospitals Reduce Infections, Saving Up to an Estimated $75M Since 2007
Pennsylvania Hospitals Reduce Infection Rates 3.1% From 2010-2011
Colorectal Surgical Site Infection Project Saves More Than $3.7M
